Fig. 5From: Real-world experience of erenumab in patients with chronic or episodic migraine in the UAEProportion of patients achieving < 50%, 50% to < 75%, 75% to < 100% and 100% reduction in MSMD. MSMD, monthly acute migraine-specific medication days. Percentages are based on the total number of evaluable patients at the respective visit in the full analysis setBack to article page